ArticleCommunity mental health journal2026
Patient and System Factors Associated with Second-generation Antipsychotic Metabolic Lab Monitoring, a Retrospective Cohort Study.
Article in Community mental health journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo identify patient and system factors associated with metabolic lab monitoring for patients prescribed second-generation antipsychotics (SGAs) in an outpatient psychiatry setting.
methodsThis retrospective cohort study used electronic health record data from a large academic psychiatry clinic network (April 2019–April 2024). We included adult patients with at least one visit where a clinician ordered or refilled an SGA. Data included demographics, visit details, and laboratory results. Logistic regression estimated associations with receiving any monitoring, defined as a random glucose, glycosylated hemoglobin, or lipid test. Multiple logistic regression then jointly evaluated patient and clinic characteristics that could affect monitoring.
resultsAmong 2,362 unique patients (14,135 encounters), 42.4% never received monitoring. People of older age, English as a preferred language, Black or African American Race, a Latine ethnicity, and any telehealth utilization were more likely to receive monitoring.
conclusionsIn addition to confirming persistently low rates of SGA monitoring, this study is novel in identifying specific patient and system factors that influence with whether monitoring occurs. These findings provide insights into why previous improvement efforts may not have achieved widespread success and highlight the need for targeted interventions. Future efforts should address structural barriers to lab completion, including developing workflows for facilitating in-person laboratory measurement during existing appointments and developing EHR optimizations to support lab ordering for patients at greatest risk for not receiving monitoring.
Identifiers
41954875What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.